Price
No data yet.
Social Signal Score
Revenue
$63.69M+194.62%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Todd C. Davis
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 47
- Beta
- 0.98
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 4.42
Financials
Revenue
$63.69M+194.6%Net Income
$48.51M+7432.3%EBITDA
$72.40M+761.9%Free Cash Flow
$23.99M+46.9%EPS (diluted)
$2.22+7828.6%Shares Outstanding (diluted)
21.84M-5.0%Operating Expenses
$43.79MCash & Debt
$1.36BReturn of Capital
$60.00MRevenue by Segment (annual)
$494.73MDividend per Share
$0.46Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $268.09M | $124.45M | $6.44 |
| 2024 | $167.13M | $-4.03M | $-0.22 |
| 2023 | $131.31M | $52.15M | $3.02 |
| 2022 | $196.25M | $-33.36M | $-1.98 |
| 2021 | $241.54M | $57.14M | $3.46 |
| 2020 | $163.56M | $-2.98M | $-0.18 |
| 2019 | $120.28M | $629.30M | $33.13 |
| 2018 | $251.45M | $143.32M | $5.96 |
| 2017 | $141.10M | $12.56M | $0.60 |
| 2016 | $108.97M | $-1.64M | $-0.08 |
| 2015 | $71.91M | $257.31M | $13.00 |
| 2014 | $64.54M | $12.02M | $0.59 |
| 2013 | $48.97M | $11.42M | $0.56 |
| 2012 | $31.39M | $-527.0K | $-0.03 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $9.46
- Implied price
- $274.23
- Return from $281.72
- -0.5% a year
To earn 15.0% a year on these assumptions you'd need to buy at $136.34 — -51.6% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 21 | 25 | 29 | 33 | 37 |
|---|---|---|---|---|---|
| -2.0% | -15.4% | -12.4% | -9.7% | -7.4% | -5.2% |
| 3.0% | -11.1% | -7.9% | -5.1% | -2.7% | -0.4% |
| 8.0% | -6.8% | -3.4% | -0.5% | 2.1% | 4.4% |
| 13.0% | -2.4% | 1.0% | 4.1% | 6.8% | 9.3% |
| 18.0% | 1.9% | 5.5% | 8.7% | 11.5% | 14.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- Newsglobenewswire.com·5h ago·Neutral
Ligand to Participate in September Investor Conferences JUPITER, Fla., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced its senior management team will participate in the following upcoming investor conferences: Wells Fargo Healthcare Conference 2026 (Boston): Management will participate in a fireside chat at 12:45 p.m.
View source ↗
Earnings
Thu, Nov 5(in 2 months)
Consensus estimate $2.30 per share
Typical surprise +12.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$2.37 vs $2.01beat
- Thu, May 14$1.63 vs $1.84miss
- Thu, Feb 26$2.02 vs $1.46beat
- Thu, Nov 6$3.09 vs $1.97beat
- Thu, Aug 7$1.60 vs $1.42beat
- Thu, May 8$1.33 vs $1.21beat
Estimates and results for LGND via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by LGND officers and directors.
- Bought
- —
- Sold
- $21.3m
0 trades
48 trades
- Espinoza Octaviosold
- Haas Jasonsold
- Reardon Andrewsold
- Reardon Andrewsold
- Reardon Andrewsold
- Reardon Andrewsold
- Reardon Andrewsold
- Reardon Andrewsold
52 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.